Mendus

4.90 SEK

-0.41 %

Less than 1K followers

IMMU

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

-0.41 %
+19.08 %
-15.52 %
-12.50 %
-15.22 %
-2.97 %
-85.14 %
-95.05 %
-96.30 %

Mendus develops cancer immunotherapies with a focus on the prevention of tumor recurrence, the leading cause of cancer-related deaths globally. Indications include acute myeloid leukemia, ovarian cancer and soft tissue sarcomas. The company previously went by the name Immunicum and was renamed Mendus following the merger with the Dutch private company DCprime in 2021. Mendus today has its headquarters in Stockholm and its operational activities in Leiden, The Netherlands.

Read more
Market cap
306.66M SEK
Turnover
45.77K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Latest research

Latest analysis report

Released: 2024-11-20

Latest extensive report

Released: 2024-04-10

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
8/5
2026

General meeting '26

8/5
2026

Interim report Q1'26

20/8
2026

Interim report Q2'26

ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Third party research

Mendus: CML programme commences - Edison

Mendus has announced the launch of its chronic myeloid leukaemia (CML) programme for lead immunotherapy candidate, vididencel. Preparations have been completed and regulatory clearance has been received for the Phase I VITAL-CML study, which will assess...

Mendus
Third party research

Mendus: Agreement to advance AML programme - Edison

Mendus has announced a new clinical collaboration with the Olivia Newton-John Cancer Research Institute (ONJCRI) to support the Phase Ib DIVA trial, evaluating lead cancer vaccine vididencel in chemo-unfit acute myeloid leukaemia (AML) patients. The ...

Mendus
Forum discussions
I’ve created a dedicated thread for Mendus, but my English is poor and I don’t know the industry at all, so there are bound to be mistranslations and misunderstandings. I looked up information on Inderes’ site, especially from the extensive report. Naturally, I googled for info and...
7/23/2024, 7:30 PM
by Sijoittaja-alokas
11
Tässä on Antin tuoreet kommentit Mendusin tuoreesta ilixadenceli-tutkimuksen yhteistyöstä. Mendus announced on Tuesday that the company will start a new ilixadencel trial in collaboration with the French cancer center Institut Bergonié. The trial will combine ilixadencel with the...
7/24/2024, 4:39 AM
by Sijoittaja-alokas
3
An interesting discovery, but so are many other Swedish biopharma/biotech firms. You can put money into these like a lottery ticket and maybe one eventually succeeds, while the rest engage in endless dilution of their share capital and wash away investors’ money. The discussion surrounding...
7/23/2024, 8:38 PM
by Acumen
3
MFN – 5 May 25 Mendus AB (publ): Mendus strengthens late-stage clinical developmen... Mendus AB ('Mendus' publ; IMMU. ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence, today announced the appointment of Tariq Mughal, MD FRCP FRCPath, as Chief...
5/5/2025, 12:38 PM
by Clark kent
2
Tässä on Antin yhtiöraportti Menduksen Q2:n jälkeen. For Mendus, Q2’24 marked the start of the pivotal CADENCE trial in acute myeloid leukemia (AML). The company also announced plans to restart clinical development of ilixadencel in soft tissue sarcomas (STS). In parallel, Mendus...
8/26/2024, 6:40 PM
by Sijoittaja-alokas
2
Mendus published its second-quarter report on Friday, August 23. In an interview with Antti, CEO Erik Manting summarizes what happened during the second quarter, highlights the key achievements of the CADENCE trial, and discusses the new study for the drug Ilixadencel. Inderes Mendus...
8/24/2024, 12:03 PM
by Sijoittaja-alokas
2
What’s weighing on Mendu?
11/21/2024, 3:38 PM
by Juksut
1
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.